SUMMARY OF THE STUDY
This study pooled data from two large studies conducted in Europe: TRUST (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial) and IEMO80+ (Institute for Evidence-Based Medicine in Old Age 80-Plus Thyroid Trial). Both studies included older adults with subclinical hypothyroidism (TSH 4.6–19.9 mIU/L and normal free T4) who were 65 years or older (TRUST) or 80 years or older (IEMO80+). Patients were assigned either the levothyroxine treatment or no levothyroxine group. The levothyroxine dose was progressively increased as needed every 6-8 weeks based on blood TSH levels, with the goal to normalize the TSH. Patients were followed for 12 months and had blood collected at the beginning and end of the study to measure cardiometabolic biomarkers.
A total of 286 participants (48% women, average age 75 years, average baseline TSH 6.4 mIU/L) were randomized to levothyroxine (142 patients) or no levothyroxine (144 patients). Overall, the levothyroxine treatment showed no significant improvement in cardiometabolic biomarkers in this patient population. However, further subgroup analysis indicated that participants with more severe subclinical hypothyroidism (baseline TSH ≥10 mIU/L) treated with levothyroxine had potentially beneficial reductions in most cardiometabolic biomarkers, including Total-C, LDL-C, apoB, and TG. Similarly, further analysis showed potentially favorable reductions in apoBcontaining lipoproteins (LDL and very low-density lipoprotein/VLDL), as well as other cardiometabolic biomarkers, with levothyroxine treatment in patients with a baseline TSH ≥10 mIU/L.
WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This evaluation of two large clinical trials showed that levothyroxine treatment has no significant effect overall on cholesterol levels and other cardiometabolic biomarkers in the general older adult population with subclinical hypothyroidism. Potentially favorable changes were noted only in patients with a baseline TSH ≥10 mIU/L; however, these changes were small and of uncertain clinical effect. The study findings support current clinical guidelines recommending that treatment decisions in older adults with subclinical hypothyroidism should be individualized based on baseline TSH levels. Further larger clinical trials are needed to confirm the potential benefits in patients with a baseline TSH ≥10 mIU/L.
—Elie Naous, MD, Alina Gavrila, MD, MMSC